Paquette L A
Evans Chemical Laboratories, The Ohio State University, Columbus 43210, USA.
Chem Rec. 2001;1(4):311-20. doi: 10.1002/tcr.1016.
The structural designation A originally made by Sharma and Alam to sclerophytin A was considered to be ambiguous and so notably strained relative to B that the latter was targeted for de novo synthesis (Scheme 1). Our two successful routes began with (5S)-(d-menthyloxy)-2(5H)-furanone and involved the application of cycloaddition, Claisen ring expansion, transannular oxymercuration, and 1,2-carbonyl transposition tactics to arrive at B. It was immediately apparent from polarity considerations and spectroscopic data that the antileukemic marine metabolite in question was in need of more deep-seated structural revision. Following close re-examination of an acquired authentic sample by advanced NMR techniques, the strong inference was made that sclerophytin A actually lacked a second oxygen bridge and was in reality the triol C. This conclusion was unequivocally confirmed by diverting an advanced intermediate generated earlier into a short sequence beginning with regiocontrolled dihydroxylation and terminating with configurational inversion at the secondary carbinol center. The status of other members of this series is also presented.
夏尔马和阿拉姆最初给硬叶植物素A指定的结构名称A被认为含糊不清,而且相对于B来说张力特别大,因此后者成为从头合成的目标(方案1)。我们的两条成功路线从(5S)-(d-薄荷氧基)-2(5H)-呋喃酮开始,涉及环加成、克莱森环扩张、跨环氧汞化和1,2-羰基迁移策略,以得到B。从极性考虑和光谱数据可以立即看出,所讨论的抗白血病海洋代谢物需要进行更深入的结构修正。通过先进的核磁共振技术对获取的真实样品进行仔细重新检查后,有强有力的推断认为硬叶植物素A实际上缺少第二个氧桥,实际上是三醇C。通过将早期生成的高级中间体引入一个简短的序列中,该序列从区域控制的二羟基化开始,在仲甲醇中心进行构型翻转结束,这一结论得到了明确证实。还介绍了该系列其他成员的情况。